Mycronic AB

As of June 30, 2026, Mycronic AB carries a market capitalization of 5.77B, placing it among publicly traded companies globally. Its enterprise value stands at 5.56B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Mycronic AB's next confirmed earnings release is scheduled for February 4, 2027.

As of June 30, 2026, Mycronic AB has 195.27M shares outstanding.

As of June 30, 2026, Mycronic AB trades at a trailing price-to-earnings ratio of 32.52. The price-to-sales ratio is 7.09, and the price-to-book ratio stands at 8.11.

As of June 30, 2026, Mycronic AB trades at an EV/EBITDA multiple of 24.38 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 6.84 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 24.38 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Mycronic AB trades at an EV/FCF ratio of 28.48, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 5.56B versus a market cap of 5.77B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Mycronic AB maintains a current ratio of 2.22, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Mycronic AB posted a return on equity (ROE) of 26.30, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 25.14 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 17.22, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 25.26, useful for judging operating efficiency across full business cycles. The company generates approximately 324,779.11 in revenue per employee across its workforce of 2,503.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.78 indicates how many times Mycronic AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Mycronic AB recorded 51.64M in income tax expense. That works out to an effective tax rate of 22.56, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 228.87M, leaving 177.41M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 6, 2026, Mycronic AB's stock has gained approximately 56.94% over the past 52 weeks. The 50-day moving average sits at 29.03, while the 200-day moving average is 24.79.

Over the twelve months ended June 30, 2026, Mycronic AB generated 813.08M in revenue and converted that into 177.41M in net income, yielding earnings per share of 0.91. EBITDA reached 228.23M, while operating income came in at 228.23M.

As of June 30, 2026, Mycronic AB holds 242.59M in cash and equivalents against 37.92M in total debt, resulting in a net debt position of -242.59M. Total book value stands at 711.52M, with working capital of 363.84M providing operational flexibility.

Mycronic AB produced 195.37M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Mycronic AB posted a gross margin of 54.85, reflecting its pricing power and cost economics. The operating margin of 28.07 and net profit margin of 21.82 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 3.39, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.32, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Mycronic AB shareholders.

Mycronic AB's most recent stock split took place on June 3, 2025 with a 1:2 split ratio.